Cited by 186CRISPR and Genetic EngineeringCAR-T cell therapy researchVirus-based gene therapy research

The DOI matches its Crossref record; 75 of the 77 references it cites were found in a registry or an index; 4 of the 46 sources its claims cite were checked for support.

Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies

Open access

Abstract

SUMMARY Adoptive transfer of genetically-modified immune cells holds great promise for cancer immunotherapy. CRISPR knock-in targeting can improve cell therapies, but more high-throughput methods are needed to test which knock-in gene constructs most potently enhance primary cell functions in vivo. We developed a widely adaptable technology to barcode and track targeted integrations of large non-viral DNA templates, and applied it to perform pooled knock-in screens in primary human T cells. Pooled knock-in of dozens of unique barcoded templates into the TCR-locus revealed gene constructs that enhanced fitness in vitro and in vivo. We further developed Pooled Knock-In Sequencing (PoKI-Seq), combining single-cell transcriptome analysis and pooled knock-in screening to measure cell abundance and cell state ex vivo and in vivo. This platform nominated a novel TGFβR2–41BB chimeric receptor that improved solid tumor clearance. Pooled knock-in screening enables parallelized re-writing of endogenous genetic sequences to accelerate discovery of knock-in programs for cell therapies.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.cell.2020.03.039

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

58 Own result · 39 Own interpretation · 22 Not checked yet · 8 Own method · 6 No basis given · 2 Supported

Verify all 42 references — free account
  • It may state two separate claims as one. 36
  • Probably not a substantial claim. 13
45 of 45
  • The paper relies on this without support.

    The field lacks rapid methods to test and directly compare the functions of large DNA knock-in integrations in human primary cells.

    “However, to date we have lacked rapid methods to test and directly compare the functions of large DNA knock-in integrations in human primary cells, which would accelerate the development of more effective cell therapies.”
  • The paper relies on this without support.

    Cell abundance alone is insufficient to assess cellular function, and an ideal screening method should also assess modified cell states.

    “However, cell abundance measures only one aspect of cellular function, and an ideal screening methodology would allow systematic assessment of modified cell states as well.”
  • The paper relies on this without support.

    The in vitro conditions used in the pooled screens mimic aspects of tumor microenvironments.

    “we repeated the pooled screen in diverse in vitro conditions designed to mimic aspects of tumor micro-environments”
  • The paper relies on this without support.

    CAR T cells have not proved effective for solid tumors.

    “CAR T cells are now approved therapy for some hematological malignancies, but have not proved effective for solid tumors.”
  • The paper relies on this without support.

    For many clinical applications, engineering antigen specificity alone will not be sufficient to cure disease.

    “Mounting evidence suggests that for many clinical applications engineering antigen specificity will not be sufficient to cure disease.”
  • The paper relies on this without support.

    T cell function is often suppressed by tumors, and further engineering of antigen-specific T cells is required to promote more effective cell states.

    “For example, T cell function is often suppressed by tumors and further engineering of antigen-specific T cells will be required to promote more effective cell states.”
  • The paper relies on this without support.

    The field needs a systematic approach to compare complex transgene constructs head-to-head and determine which are most effective for specific disease indications.

    “The field needs a systematic approach to compare complex transgene constructs head-to-head and determine which are most effective for specific disease indications.”
  • The paper relies on this without support.

    Technical challenges have limited CRISPRa applications in therapeutically relevant primary human cell types.

    “Technical challenges have limited CRISPRa applications in therapeutically relevant primary human cell types.”
  • The paper relies on this without support.

    CRISPRa can only induce natural gene products encoded in the genome and does so with variable efficiency.

    “Furthermore, CRISPRa can only induce natural gene products encoded in the genome and does so with variable efficiency.”
  • The paper relies on this without support.

    A major challenge to quantitative tracking of targeted genomic integrations of pooled knock-in constructs has been the abundance of non-integrated DNA templates in targeted cells and the risk of template switching during molecular steps of pooled library production, integration, and sequencing.

    “A major challenge to quantitative tracking of targeted genomic integrations of pooled knock-in constructs has been the abundance of non-integrated DNA templates (viral or non-viral) in targeted cells and the risk of template switching during molecular steps of pooled library production, integration, and sequencing.”
  • The paper relies on this without support.

    Most over-expression studies have been performed with lentiviral or retroviral vectors.

    “Most over-expression studies have been performed with lentiviral or retroviral vectors.”
  • The authors state this as an assumption.

    Template switching is random, and any barcode that is swapped is equally likely to switch to any other barcode.

    “Assumption 1: Template switching is random, and any barcode that is swapped is equally likely to switch to any other barcode.”
  • The authors state this as an assumption.

    A template that has switched once is equally likely to switch again.

    “Assumption 2: A template that has switched once is equally likely to switch again.”
  • The authors state this as an assumption.

    The knock-in library is arbitrarily large.

    “assuming an arbitrarily large knock-in library”
14 of 14

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 77 references

Cited by

Sorted by citations

See all 186

Metadata

Authors
Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., Hiatt, J., Wu, D., Nguyen, D. N., Goodman, D., Bluestone, J. A., Ye, C. J., Roybal, K., Shifrut, E., & Marson, A.
Affiliations
University of California, San Francisco (US)
Corresponding author
  • Roth, Theodore L.
  • Marson, Alexander
Venue
Cell
Publisher
Elsevier BV
Published
2020-04
Volume
181
Issue
3
Pages
728-744.e21
ISSN
0092-8674 (ISSN-L)
OpenAlex
W3017040524
Cited by
186
References
77
Citations by year
2026: 11 · 2025: 23 · 2024: 25 · 2023: 29 · 2022: 45 · 2021: 32 · 2020: 19
FWCI
10.13
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
National Institutes of Health
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
T cell engineering, adoptive immunotherapy, barcoding, single-cell transcriptomics, cancer immunotherapy
MeSH terms
RNA, Guide, CRISPR-Cas Systems, Animals, Blood Cells, Genetic Engineering, Humans, Immunotherapy, T-Lymphocytes, Mice, SCID, Mice, Inbred NOD, Mice, Gene Knock-In Techniques, Single-Cell Analysis, Transcriptome, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review